苯扎贝特对高甘油三酯血症并高血压患者炎性细胞因子和血压的影响被引量：5

The effect of bezafibrate on serum pro-inflammatory cytokine levels and blood pressure in hypertriglyceridemic and hypertensive patients

在线阅读下载PDF

导出

摘要目的　观察苯扎贝特治疗后高甘油三酯血症合并高血压患者血浆炎性细胞因子和血压的变化。方法　58例高甘油三酯血症合并原发性高血压患者,在常规缓释硝苯地平降压治疗的基础上随机分为苯扎贝特组和安慰剂组,观察治疗前后血脂和血清高敏C 反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF -)和白介素 6(IL-6)水平的变化,以及与血压变化的关系。结果　苯扎贝特组治疗后血清总胆固醇、甘油三酯、低密度脂蛋白胆固醇水平较治疗前显著降低(P<0.05),高密度脂蛋白胆固醇水平显著升高(P<0.05), 血糖、尿酸水平也有显著下降(P<0.05),血清hs CRP和TNF-α水平显著降低(P<0.05);安慰剂组上述指标无显著变化。苯扎贝特组血清hs-CRP和TNF -水平的变化与甘油三酯水平呈显著正相关(P<0.05)。苯扎贝特组舒张压的下降幅度显著大于安慰剂组 (P<0.05),而且与血甘油三酯水平的变化呈显著正相关(P<0.005)。结论　苯扎贝特可能通过调整血脂异常抑制血循环中炎性细胞因子的表达,并且可能在降压药物治疗的基础上使血压进一步降低。 Objective To investigate the effect of bezafibrate on serum pro-inflammatory cytokine levels and blood pressure change in patients with hypertriglyceridemia and hypertension after antihypertensive therapy with extended release nifedipine. Methods Fifty-eight patients with both hypertriglyceridemia and hypertension, which was treated with extended release nifedipine, were randomized into 2 groups: bezafibrate group (n=30) and placebo group (n=28). Changes in levels of blood lipids, high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factorα(TNF-α) and interleukin-6 (IL-6) were observed following the treatment. A correlation between these changes and blood pressure was analyzed in both groups. Results The levels of triglyceride, total and low density lipoprotein cholesterol were significantly reduced (P<0.05), high density lipoprotein cholesterol increased (P<0.05), and blood glucose and uric acid decreased (P<0.05) in bezafibrate group, while the changes in placebo group did not reach statistical significance. Furthermore, the levels of hs-CRP and TNF-α were significantly lowered in bezafibrate group (P<0.05 or P<0.01), but no obvious change was observed in placebo group. The levels of hs-CRP and TNF-α were found to be positively correlated with that of triglyceride in bezafibrate group (P<0.05) by multifactor linear regression analysis. The reduction of diastolic blood pressure (DBP) in bezafibrate group was obviously greater than that in placebo group (P<0.05), and a positive correlation was found between the reduction of DBP and the change in triglyceride level (P<0.005). Conclusion Bezafibrate may inhibit circulating pro-inflammatory cytokines expression by correcting dyslipidemia, and also have an additional blood pressure-lowering effect after antihypertensive therapy in patients with hypertriglyceridemia and hypertension.

作者叶平苏工张铖

机构地区解放军总医院老年心内科

出处《解放军医学杂志》 CAS CSCD 北大核心 2005年第3期216-218,共3页 Medical Journal of Chinese People's Liberation Army

关键词苯扎贝特高血压高甘油三酯血症趋化因子类 bezafibrate hypertension hypertriglyceridemia chemokines

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献11

1叶平.过氧化体增殖物激活受体与脂质代谢[J].中国动脉硬化杂志,1999,7(4):369-372. 被引量：13
2Staels B, Koening W, Habib A et al. Activation of human aortic smooth muscle cell is inhibited by PPARα but not by PPARγ activators. Nature, 1998, 393(6687):790.
3Wierzbicki AS. Lipid lowering: another method of reducing blood pressure? J Hum Hypertens, 2002, 16(11):753.
4Diep QN, Benkirane K, Amiri F et al. PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Hum Mole Cell Cardiol, 2004, 36(2):295.
5Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular disease. Med Hypoth, 2004, 62(3):499.
6Mohrschladt MF, Weverling-Rijsburger AW, de Man FH et al. Hypertriglyceridemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy. Atherosclerosis, 2000, 148(2):413.
7Neve BP, Corseaux D, Chinetti G et al. PPARα agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation, 2001, 103(2):207.
8Jonkers IJ, Mohrschladt MF, Westendorp RG et al. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med, 2002, 112(2):275.
9Grundy SM. Inflammation, hypertension, and the metabolic syndrome. JAMA, 2003, 290(22):3000.
10Schiffrin EL, Amiri F, Benkirane K et al. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension, 2003, 42(4):664.

二级参考文献15

1徐成斌叶平.血脂异常的药物治疗[A].见: 叶平 (主编).血脂的基础和临床[C].北京: 人民军医出版社,2002.435.
2Su J L，Hybridoma，1999年，18卷，273页
3Tsai M J，Annu Rev Biochem，1994年，63卷，451页
4蒋文平.钙通道阻滞剂[A].见:刘力生主编.高血压[M].人民卫生出版社,2001.1156-1195.
5Ellen G. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123(endothelin receptor subtype an antagonist) on blood pressure in hypertensive rats[J].Am J hypertens,1993,6:667.
6Ferro CJ, Webb DJ. Endothelial dysfunction and hypertension[J].Drugs,1997,53:30-41.
7Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat[J].Hypertension,1998,31:225-231.
8Neaton JD, Blackburn H, et al. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial: multiple risk factor intervention trial research group[J].Arch Intern Med,1992,152:1490-1500.
9Shimokawa H. Primary endothelial dysfunction: atherosclerosis[J].J Mol Cell Cardiol,1999,31:23-37.
10Anderson TJ. Assessment and treatment of endothelium dysfunction in humans[J].JACC,1999,34(3):631-638.